Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy for Anxiety and Depression: a Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Salivary oxytocin
研究概览
简要总结
The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance).
There will be no interference with the usual clinical routine in our Service. The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment.
Participants will be asked to give 4 saliva samples the day of their LSD treatment .In addition they will fill-in self-report questionnaires which are part of the clinical routine
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ongoing psychotherapy with a certified psychotherapist, anxiety disorder or depression resistant to usual treatments, agreement to stop necessary medication
排除标准
- •Exclusion: psychotic or bipolar disorder, high suicidal risk, severe cardiovascular disease, severe liver disease, neurological disease of the central nervous system, pregnancy and breastfeeding
结局指标
主要结局
Salivary oxytocin
时间窗: the day of treatment administration (one day)
oxytocin sampled in the saliva
次要结局
- Self-reported symptoms of anxiety (STAI-T)(over 6 months)
- Self-reported depressive symptoms (BDI-II)(over 6 months)
- Self-reported intensity of mystical experience(The 1 day of treatment administration)
- Self-reported intensity of Connectedness(The 1 day of treatment administration)
研究者
Tatiana Aboulafia Brakha
Principal Investigator-Head of psychologists
University of Geneva, Switzerland